Case Studies

Streamlining Cardiac Care at Manchester University

HeartFlow would like to take a moment to recognise sites that are going above and beyond to deliver an outstanding CT service to patients, especially during this COVID pandemic.

We are excited and proud to recognise Manchester University NHS Foundation Trust (MFT) for their Outstanding CT Service!

Overview of Manchester University NHS Foundation Trust’s CT service

  • Extensive high-volume cardiac CT service at MFT, performing ~4000 scans per year
  • Highly skilled CT radiographers with specialist cardiac training
  • As well as serving the local community, the service acts as a regional hub for Greater Manchester, extending the service to surrounding hospitals without cardiac CT capabilities
  • Great learning centre for fellows, registrars, and radiographers on cardiac CT due to the high volumes performed at MFT

Changes to CT service due to COVID

  • Guidance to referrers encouraging prescription of oral beta-blockers as pre-medication
    • Shorter scan appointment with less time spent in hospital
    • Lower requirement for intravenous beta-blockade and shorter post-scan observation time
    • Higher quality imaging & increased suitability for combined FFRCT assessment
  • Increased number of lists per week to exceed a pre-COVID level of capacity, even with more stringent cleaning procedures
  • Increased access to in-patient slots for low-probability ACS to facilitate rapid discharge
  • Increased staff flexibility with daily tasks based on the unpredictability of the environment
    • Due to the constantly changing environment, MFT staff are comfortable changing their routine and stepping into roles that aren’t traditionally theirs
    • Depending on scheduling rotations, the staff can jump in to perform tasks with higher exposure to patients if other colleagues on staff need to shield to ensure cardiac services run without interruptions
    • For example, a colleague required to shield will focus on reporting while another consultant will jump in to prescribe any intravenous beta blockers as necessary between working on other admin tasks

Their CT departments have been at the forefront of the fight against the COVID-19 pandemic driven by the surge in diagnostic chest imaging requirements. Accordingly, the CT units and staff had to rapidly adapt to social distancing and Personal Protective Equipment protocols; however, this provided the foundation to continue an uninterrupted coronary CT service which was fundamental in maintaining a rapid access chest pain clinic (RACPC) service throughout the pandemic, and in particular took some of the burden away from exercise stress imaging modalities limited by aerosol-generating procedure restrictions.

One additional impact has been that the spectrum of patients with chest pain assessed by a CT-first strategy in accordance with the latest NICE guidelines has increased. It’s a trend MFT expects to continue in a post-COVID environment particularly as tools such as HeartFlow further increase the diagnostic value of coronary CT by adding a physiologic element to the anatomical stenosis and plaque burden assessment.

In summary, Manchester University NHS Foundation Trust has adapted their CT protocols and day to day tasks to ensure they are able to continue to offer their patients uninterrupted access to the best standard of cardiac care, even during this COVID pandemic. We, at HeartFlow, are proud to be working with them to enhance heart care for their patients.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please apply for research grants through our online submission form.

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.